Recent Advances in Anticancer Chemotherapeutics based upon Azepine Scaffold
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, Sarbjit | - |
dc.contributor.author | Goo, Jail | - |
dc.contributor.author | Gajulapati, Veeraswamy | - |
dc.contributor.author | Chang, Tong-Shin | - |
dc.contributor.author | Lee, Kyeong | - |
dc.contributor.author | Choi, Yongseok | - |
dc.date.accessioned | 2021-09-04T05:05:49Z | - |
dc.date.available | 2021-09-04T05:05:49Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1871-5206 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/90187 | - |
dc.description.abstract | In the recent few years, the emergence of heterocyclic ring-containing anti-cancer agents has gained a great deal of attention among medicinal chemists. Among these, azepine-based compounds are particularly becoming attractive recently. In this Focus Review, we highlight the recent advancements in the development of azepine-based anti-cancer compounds since the year 2000. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BENTHAM SCIENCE PUBL LTD | - |
dc.subject | GERANYLGERANYLTRANSFERASE-I INHIBITORS | - |
dc.subject | NUCLEOSOME CORE PARTICLE | - |
dc.subject | STRUCTURE-BASED DESIGN | - |
dc.subject | P-GLYCOPROTEIN | - |
dc.subject | 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE | - |
dc.subject | PROTEASOME INHIBITORS | - |
dc.subject | BIOLOGICAL EVALUATION | - |
dc.subject | DERIVATIVES BEARING | - |
dc.subject | RECENT PROGRESS | - |
dc.subject | CELL LINES | - |
dc.title | Recent Advances in Anticancer Chemotherapeutics based upon Azepine Scaffold | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Yongseok | - |
dc.identifier.doi | 10.2174/1871520615666150916091750 | - |
dc.identifier.scopusid | 2-s2.0-84964000553 | - |
dc.identifier.wosid | 000373800300002 | - |
dc.identifier.bibliographicCitation | ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, v.16, no.5, pp.539 - 557 | - |
dc.relation.isPartOf | ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | - |
dc.citation.title | ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | - |
dc.citation.volume | 16 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 539 | - |
dc.citation.endPage | 557 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.subject.keywordPlus | GERANYLGERANYLTRANSFERASE-I INHIBITORS | - |
dc.subject.keywordPlus | NUCLEOSOME CORE PARTICLE | - |
dc.subject.keywordPlus | STRUCTURE-BASED DESIGN | - |
dc.subject.keywordPlus | P-GLYCOPROTEIN | - |
dc.subject.keywordPlus | 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE | - |
dc.subject.keywordPlus | PROTEASOME INHIBITORS | - |
dc.subject.keywordPlus | BIOLOGICAL EVALUATION | - |
dc.subject.keywordPlus | DERIVATIVES BEARING | - |
dc.subject.keywordPlus | RECENT PROGRESS | - |
dc.subject.keywordPlus | CELL LINES | - |
dc.subject.keywordAuthor | Anticancer agents | - |
dc.subject.keywordAuthor | azepane scaffold | - |
dc.subject.keywordAuthor | chemotherapeutics | - |
dc.subject.keywordAuthor | histone deacetylases | - |
dc.subject.keywordAuthor | kinase inhibitors | - |
dc.subject.keywordAuthor | tubulin inhibitors | - |
dc.subject.keywordAuthor | phototherapeutic agents | - |
dc.subject.keywordAuthor | hormone modulators | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.